Reaction
Reticulocyte Count Increased reporting signals
As of the last recalculation, Reticulocyte Count Increased appears in 801 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 154.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 231 | 154.8 | 155.5 |
| Ravulizumab | 43 | 87.3 | 87.6 |
| Deferasirox | 42 | 43.4 | 43.4 |
| Hydroxyurea | 22 | 27.8 | 27.8 |
| Alemtuzumab | 20 | 27.5 | 27.6 |
| Inclisiran | 8 | 26.2 | 26.2 |
| Busulfan | 15 | 25.2 | 25.2 |
| Voxelotor | 20 | 23.7 | 23.8 |
| Brentuximab Vedotin | 8 | 20.5 | 20.5 |
| Erythropoietin | 13 | 16.7 | 16.7 |
| Eltrombopag Olamine | 12 | 13.7 | 13.7 |
| Crizotinib | 4 | 8.2 | 8.2 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 7.1 | 7.1 |